Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury - PubMed (original) (raw)
doi: 10.1089/neu.2006.003789.
Stephen B Lewis, Alex B Valadka, Linda Papa, H Julia Hannay, Shelley C Heaton, Jason A Demery, Ming Cheng Liu, Jada M Aikman, Veronica Akle, Gretchen M Brophy, Joseph J Tepas, Kevin K W Wang, Claudia S Robertson, Ronald L Hayes
Affiliations
- PMID: 17375999
- DOI: 10.1089/neu.2006.003789
Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury
Jose A Pineda et al. J Neurotrauma. 2007 Feb.
Abstract
Following traumatic brain injury (TBI), the cytoskeletal protein alpha-II-spectrin is proteolyzed by calpain and caspase-3 to signature breakdown products. To determine whether alpha -II-spectrin proteolysis is a potentially reliable biomarker for TBI in humans, the present study (1) examined levels of spectrin breakdown products (SBDPs) in cerebrospinal fluid (CSF) from adults with severe TBI and (2) examined the relationship between these levels, severity of injury, and clinical outcome. This prospective case control study enrolled 41 patients with severe TBI, defined by a Glasgow Coma Scale (GCS) score of < or =8, who underwent intraventricular intracranial pressure monitoring. Patients without TBI requiring CSF drainage for other medical reasons served as controls. Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, and 120 h following TBI and analyzed for SBDPs. Outcome was assessed using the Glasgow Outcome Score (GOS) 6 months after injury. Calpain and caspase-3 mediated SBDP levels in CSF were significantly increased in TBI patients at several time points after injury, compared to control subjects. The time course of calpain mediated SBDP150 and SBDP145 differed from that of caspase-3 mediated SBDP120 during the post-injury period examined. Mean SBDP densitometry values measured early after injury correlated with severity of injury, computed tomography (CT) scan findings, and outcome at 6 months post-injury. Taken together, these results support that alpha -II-spectrin breakdown products are potentially useful biomarker of severe TBI in humans. Our data further suggests that both necrotic/oncotic and apoptotic cell death mechanisms are activated in humans following severe TBI, but with a different time course after injury.
Similar articles
- Detection of alphaII-spectrin and breakdown products in humans after severe traumatic brain injury.
Cardali S, Maugeri R. Cardali S, et al. J Neurosurg Sci. 2006 Jun;50(2):25-31. J Neurosurg Sci. 2006. PMID: 16841024 - Spectrin breakdown products in the cerebrospinal fluid in severe head injury--preliminary observations.
Farkas O, Polgár B, Szekeres-Barthó J, Dóczi T, Povlishock JT, Büki A. Farkas O, et al. Acta Neurochir (Wien). 2005 Aug;147(8):855-61. doi: 10.1007/s00701-005-0559-6. Epub 2005 Jun 9. Acta Neurochir (Wien). 2005. PMID: 15924207 - αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients.
Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, Robertson C, Buki A, Scharf D, Jixiang M, Akinyi L, Muller U, Wang KK, Hayes RL. Mondello S, et al. J Neurotrauma. 2010 Jul;27(7):1203-13. doi: 10.1089/neu.2010.1278. J Neurotrauma. 2010. PMID: 20408766 Free PMC article. - The role of spectrin breakdown products in patients with traumatic brain injury: a systematic review and meta-analysis.
Liu Y, Yao X, Lv X, Qian J. Liu Y, et al. Neurol Sci. 2023 Apr;44(4):1171-1183. doi: 10.1007/s10072-022-06558-y. Epub 2022 Dec 22. Neurol Sci. 2023. PMID: 36547778 Review. - Calpain as a therapeutic target in traumatic brain injury.
Saatman KE, Creed J, Raghupathi R. Saatman KE, et al. Neurotherapeutics. 2010 Jan;7(1):31-42. doi: 10.1016/j.nurt.2009.11.002. Neurotherapeutics. 2010. PMID: 20129495 Free PMC article. Review.
Cited by
- Fluid biomarkers for mild traumatic brain injury and related conditions.
Zetterberg H, Blennow K. Zetterberg H, et al. Nat Rev Neurol. 2016 Oct;12(10):563-74. doi: 10.1038/nrneurol.2016.127. Epub 2016 Sep 16. Nat Rev Neurol. 2016. PMID: 27632903 Review. - Differential Neuroproteomic and Systems Biology Analysis of Spinal Cord Injury.
Moghieb A, Bramlett HM, Das JH, Yang Z, Selig T, Yost RA, Wang MS, Dietrich WD, Wang KK. Moghieb A, et al. Mol Cell Proteomics. 2016 Jul;15(7):2379-95. doi: 10.1074/mcp.M116.058115. Epub 2016 May 5. Mol Cell Proteomics. 2016. PMID: 27150525 Free PMC article. - Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage.
Siman R, Giovannone N, Toraskar N, Frangos S, Stein SC, Levine JM, Kumar MA. Siman R, et al. PLoS One. 2011;6(12):e28938. doi: 10.1371/journal.pone.0028938. Epub 2011 Dec 9. PLoS One. 2011. PMID: 22174930 Free PMC article. - Biomarkers in traumatic brain injury.
Sharma R, Laskowitz DT. Sharma R, et al. Curr Neurol Neurosci Rep. 2012 Oct;12(5):560-9. doi: 10.1007/s11910-012-0301-8. Curr Neurol Neurosci Rep. 2012. PMID: 22811071 Review. - Blood-based diagnostics of traumatic brain injuries.
Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK. Mondello S, et al. Expert Rev Mol Diagn. 2011 Jan;11(1):65-78. doi: 10.1586/erm.10.104. Expert Rev Mol Diagn. 2011. PMID: 21171922 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials